Codeine Syrup under NDPS Act: MP HC's Recent Ruling

In the realm of pharmaceutical regulations and narcotics control, one pressing question has sparked significant judicial scrutiny: Recent MP HC Judgment Whether Syrup Containing Codeine Falls under NDPS Act. Cough syrups like Phensedyl, containing codeine phosphate, are commonly used for therapeutic purposes, yet their possession in large quantities often leads to NDPS Act charges. This blog delves into the nuances of the Madhya Pradesh High Court's (MP HC) recent judgment, key precedents, and regulatory frameworks to clarify when such syrups attract NDPS penalties.

The Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985, strictly regulates narcotic drugs and psychotropic substances. However, codeine-based cough syrups occupy a gray area, balancing medicinal utility under the Drugs and Cosmetics Act against potential abuse. Recent rulings emphasize context—quantity, licensing, and intent—as pivotal factors. This analysis draws from authoritative judgments to provide clarity, though it is for informational purposes only and not a substitute for professional legal advice.

Key Findings from the MP HC Judgment

The MP HC meticulously examined the classification of cough syrups containing codeine phosphate. Central to the ruling was the definition of a manufactured drug under the NDPS Act. The court held that syrups produced by licensed manufacturers and adhering to prescribed codeine limits do not qualify as narcotic drugs under the Act. 2015 0 Supreme(MP) 948 2014 0 Supreme(All) 3863

• Possession Limits: Possession is permissible within specified quantities. Exceeding these triggers NDPS provisions. For example, 10,600 bottles of Phensedyl, laden with substantial codeine, was classified as commercial quantity contraband. 2022 0 Supreme(Del) 1852

• Therapeutic Use Exception: As Schedule 'H' drugs under the Drugs and Cosmetics Act, these syrups are exempt from NDPS penalties if held for legitimate medical use and within limits. Evidence of diversion for abuse, however, invokes strict NDPS measures. 2014 0 Supreme(All) 3863 2017 0 Supreme(J&K) 617

This distinction underscores that not all codeine-containing syrups are inherently narcotic; regulatory compliance is key.

Legal Precedents Shaping the Debate

Judicial interpretations have evolved, with several High Courts weighing in. The Allahabad High Court in Ashok Kumar Vs. Union of India ruled that possession of Phensedyl by licensed stockists within limits does not attract NDPS penalties.

Arvind Kumar vs State - Delhi (2020)

Similarly, in a Chhattisgarh High Court case, 47 pieces of Rax Cough Syrup containing codeine were scrutinized, with Section 37 of the NDPS Act invoked due to commercial quantity. The court noted: codene – which comes within the commercial quantity, was seized from the applicant.

SADDAM HUSSAIN vs STATE OF CHHATTISGARH - Chhattisgarh

In Madhya Pradesh, a case involving two boxes of 240 bottles of S-KUF-Codeine Phosphate syrup (100 ml each) led to charges under Sections 8, 21, and 22 of the NDPS Act. 2024 Supreme(Online)(MP) 7409

The Himachal Pradesh High Court referred the issue of whether such syrups are 'manufactured drugs' to a larger bench in Deepak Rawat vs. State of H.P. (2024), highlighting ongoing complexity. 2025 Supreme(Online)(HP) 8689 Courts like in Hemant Kumar Saini (2021) affirmed exemptions for licensed possession under Notification Entry 35 dated 14-11-1985. 2021 0 Supreme(All) 1129

Another precedent quashed proceedings, holding: Phensedyl Cough Syrup falls within the exception provided under the NDPS Act and therefore its possession with licenced stockists should not invite the penalties under the NDPS Act... no offence under Section 8/21 read with Section - 29 NDPS Act is made out. 2021 0 Supreme(Ori) 168

Commercial Quantity and Quantitative Analysis

Determining commercial vs. small quantity is crucial for bail, sentencing, and penalties. The MP HC stressed evaluating total syrup weight alongside narcotic content. 2020 0 Supreme(Del) 763 2021 0 Supreme(MP) 324

• In one instance, 98 bottles with 9.8 grams of codeine was deemed small quantity, easing NDPS rigors. 2023 0 Supreme(Pat) 124
• Bail applications often succeed if trial delays persist and compliance is shown, as in a case where the appellant argued lack of conscious possession after over a year in jail. 2024 0 Supreme(P&H) 1290

Courts consistently direct weighing pure codeine content against neutral syrup base for threshold calculations. 2023 0 Supreme(HP) 356 2022 0 Supreme(Del) 1905

Regulatory Framework: NDPS Act vs. Drugs and Cosmetics Act

Codeine syrups are governed dually:

• Drugs and Cosmetics Act: Regulates manufacture, sale, and distribution as medicines.
• NDPS Act: Targets narcotics, but exempts therapeutic formulations from licensed sources. 2022 0 Supreme(Cal) 1254 2024 0 Supreme(Cal) 200

Notifications like the 1985 Entry 35 provide carve-outs, yet misuse—evidenced by diversion—nullifies exemptions. The debate persists: Are these 'narcotic drugs' or mere 'manufactured drugs'? Therapeutic intent typically shields compliant parties.

Mohd. Ahsan vs Customs - Delhi

Practical Implications and Compliance Tips

For pharmacists, stockists, and consumers:

• Maintain Documentation: Licenses, invoices, and prescriptions prove therapeutic use.
• Monitor Quantities: Adhere to NDPS-prescribed limits to avoid commercial quantity tags.
• Avoid Diversion Risks: Large, unlicensed holdings invite scrutiny.

Legal practitioners must assess facts holistically—quantity, source, and purpose—before NDPS applicability. 2022 0 Supreme(Del) 1905

Conclusion and Key Takeaways

The MP HC's judgment clarifies that cough syrups containing codeine may not fall under the NDPS Act if within limits, licensed, and for therapeutic use. However, excesses or misuse trigger penalties. This nuanced stance aligns with precedents emphasizing context over blanket classification.

Key Takeaways:- Licensed, limited possession generally exempt. 2014 0 Supreme(All) 3863- Commercial quantities (e.g., thousands of bottles) invoke NDPS. 2022 0 Supreme(Del) 1852- Courts favor exemptions for medicinal compliance. 2021 0 Supreme(Ori) 168- Ongoing referrals signal evolving jurisprudence. 2025 Supreme(Online)(HP) 8689

Ensure dual compliance with NDPS and Drugs Acts. Consult legal experts for case-specific guidance—this post offers general insights only.

References: 2015 0 Supreme(MP) 948 2014 0 Supreme(All) 3863 2022 0 Supreme(Del) 1852

Arvind Kumar vs State - Delhi (2020)

SADDAM HUSSAIN vs STATE OF CHHATTISGARH - Chhattisgarh

Mohd. Ahsan vs Customs - Delhi